Attogene
Private Company
Funding information not available
Overview
Founded in 2013, Attogene has established itself as a developer and manufacturer of diagnostic assays, primarily for environmental and food safety applications. The company's product portfolio includes kits for detecting cyanotoxins, shellfish poisons, pesticides, heavy metals, and viruses like COVID-19 and RSV. Operating as a private entity, Attogene generates revenue through direct kit sales, custom assay development services, and distribution of partner products, positioning itself at the intersection of biotechnology and environmental health.
Technology Platform
Multi-format diagnostic platform specializing in Lateral Flow Assays (with Gold, Europium, Quantum Dot, Phycoerythrin labels), Enzyme-Linked Immunosorbent Assay (ELISA), and Polymerase Chain Reaction (PCR) for detection of environmental toxins, pathogens, and contaminants.
Opportunities
Risk Factors
Competitive Landscape
Attogene competes in the broad field of life science tools and diagnostics, facing off against large players like Abcam, Thermo Fisher, and PerkinElmer in ELISA, and numerous companies in lateral flow. Its differentiation lies in its specific focus on environmental and algal toxin targets, its custom services, and its multi-label universal lateral flow platform.